

Andrew Munkacsi, Ph.D.
Sponsor: Stephen L. Sturley, Ph.D.
(Columbia University Medical Center;
New York, New York; USA)
Victoria University of Wellington, New Zealand.

Summary and plans for future funding

With this bridge funding, I will complete experiments necessary to characterize lipid reduction in the liver by Vorinostat. Then I will publish the results of these experiments in a timely publication coinciding with the Vorinostat Clinical trial that just started in September 2014. With this publication, I will submit highly competitive proposals in 2015 to NNPDF and funding agencies here in New Zealand. For example, grant proposals that I submitted in 2014 to Royal Society of New Zealand and the Health Research Council of New Zealand (the New Zealand equivalents of the NSF and NIH, respectively) to conduct the proposed research herein were not funded due to the absence of a publication demonstrating my ability to conduct experiments with mice.